Amgen Inc. v. F. Hoffmann-LaRoche LTD et al

Filing 485

DECLARATION re #482 MOTION for Summary Judgment That Claim 1 of the '422 Patent is Invalid Under 35 U.S.C. Sec. 112 of Krista M. Rycroft by F. Hoffmann-LaRoche LTD, Roche Diagnostics GmbH, Hoffmann LaRoche Inc.. (Attachments: #1 Exhibit 1#2 Exhibit 2#3 Exhibit 3#4 Exhibit 4 (part 1 of 4)#5 Exhibit 4 (part 2 of 4)#6 Exhibit 4 (part 3 of 4)#7 Exhibit 4 (part 4 of 4)#8 Exhibit 5#9 Exhibit 6#10 Exhibit 7#11 Exhibit 8#12 Exhibit 9#13 Exhibit 10 (part 1 of 4)#14 Exhibit 10 (part 2 of 4)#15 Exhibit 10, part 3 of 4#16 Exhibit 10 (part 4 of 4)#17 Exhibit 11#18 Exhibit 12#19 Exhibit 13#20 Exhibit 14#21 Exhibit 15#22 Exhibit 16#23 Exhibit 17)(Rizzo, Nicole)

Amgen Inc. v. F. Hoffmann-LaRoche LTD et al

Doc. 485

Case 1:05-cv-12237-WGY

Document 485

Filed 06/11/2007

Page 1 of 4

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS

AMGEN, INC., Plaintiff, v. F. HOFFMANN-LA ROCHE LTD, a Swiss Company, ROCHE DIAGNOSTICS GmbH, a German Company and HOFFMANN-LA ROCHE INC., a New Jersey Corporation, Defendants. DECLARATION OF KRISTA M. RYCROFT IN SUPPORT OF ROCHE'S MOTION FOR SUMMARY JUDGMENT THAT CLAIM 1 OF THE `422 PATENT IS INVALID UNDER 35 U.S.C. § 112 Lee Carl Bromberg (BBO# 058480) Julia Huston (BBO# 562160) Keith E. Toms (BBO# 663369) Nicole A. Rizzo (BBO# 663853) BROMBERG & SUNSTEIN LLP 125 Summer Street Boston, MA 02110 Tel. [phone] Leora Ben-Ami (pro hac vice) Mark S. Popofsky (pro hac vice) Patricia A. Carson (pro hac vice) Thomas F. Fleming (pro hac vice) Howard S. Suh (pro hac vice) Peter Fratangelo (BBO# 639775) Krista M. Rycroft (pro hac vice) KAYE SCHOLER LLP 425 Park Avenue New York, New York 10022 Tel. [phone] Counsel for Defendants, F. HOFFMANN-LA ROCHE LTD, ROCHE DIAGNOSTICS GmbH, and HOFFMANN-LA ROCHE INC. 1
Dockets.Justia.com

Civil Action No. 05-12237 WGY U.S. District Judge Young

Dated: June 11, 2007

Case 1:05-cv-12237-WGY

Document 485

Filed 06/11/2007

Page 2 of 4

I, Krista M. Rycroft, hereby declare under penalty of perjury that: 1. I am an attorney admitted to the Bar of the State of New York and am an

associate in the law firm of Kaye Scholer LLP, counsel for Defendants in the above-captioned case. 2. I make this declaration in support of Roche's Motion for Summary Judgment That

Claim 1 of the `422 Patent Is Invalid Under 35 U.S.C. §112 and the accompanying Rule 56.1 Statement Of Undisputed Material Facts. 3. 4. Exhibit 1 is a true and correct copy of U.S. Patent No. 5,955,422. Exhibit 2 is a true and correct copy of Amgen Inc.'s Response to Defendants'

Claim Construction Brief filed March 19, 2007 (Docket No. 323). 5. Hearing. 6. Exhibit 4 is a true and correct copy of Amgen Inc.'s Post-Hearing Memorandum Exhibit 3 is a true and correct copy of excerpts from the April 17, 2007 Markman

In Support of Its Fed. R. Civ. P. 52(c) Motion That `080 Claims 2-4 Are Infringed Under The Doctrine Of Equivalents filed August 18, 2003 (AM-ITC 00852559-580). 7. Exhibit 5 is a true and correct copy of Recny et al., "Structural Characterization of

Natural Human Urinary and Recombinant DNA-derived Erythropoietin," J. Biol. Chem., 262(35); 17156-17163 (1987). 8. Exhibit 6 is a true and correct copy of excerpts from the Expert Statement of

Harvey F. Lodish, Ph.D. dated December 20, 1999, submitted in Amgen v. HMR/TKT, 97-10814WGY (D. Mass.).

2

Case 1:05-cv-12237-WGY

Document 485

Filed 06/11/2007

Page 3 of 4

9.

Exhibit 7 is a true and correct copy of an excerpt from Amgen Inc.'s September

27, 1985 Notice of Claimed Investigational Exemption for Recombinant-Human Erythropoietin (including AM-ITC 00595236-39, AM-ITC00595290-293, AM-ITC 00596039-042). 10. Exhibit 8 is a true and correct copy of Lin et al., "Cloning and expression of the

human erythropoietin gene," PNAS, 82; 7580-7584 (1985). 11. Exhibit 9 is a true and correct copy of U.S. App. Ser. No. 06/675,298 File History,

Paper 12, Exhibit 8 to the 10/2/86 Amendment and Reply. 12. Exhibit 10 is a true and correct copy of U.S. App. Ser. No. 06/675,298 File

History, Paper 12, 10/2/86 Amendment and Reply. 13. Exhibit 11 is a true and correct copy of the File History of U.S. Patent 5,955,422,

Paper 2, 11/6/90 Preliminary Amendment (AM-ITC 00899076-87). 14. Exhibit 12 is a true and correct copy of the File History of U.S. Patent 5,955,422,

Paper 33, 4/28/99 Amendment (AM-ITC 00899470-75). 15. Exhibit 13 is a true and correct copy of Lai et al., "Structural Characterization of

Human Erythropoietin," J. Biol. Chem., 261(7); 3116-3121 (1986). 16. Exhibit 14 is a true and correct copy of excerpts from the Declaration of Harvey

F. Lodish, Ph.D. In Support of Amgen Inc.'s Reply to Defendants' Claim Construction Brief, filed March 19, 2007 (Docket No. 323). 17. Exhibit 15 is a true and correct copy of excerpts from the Supplemental Expert

Report of Harvey F. Lodish, Ph.D dated June 4, 2007. 18. 2006)). Exhibit 16 is a true and correct copy of MPEP § 2173.05(d) (8th ed. Rev. 5, Aug.

3

Case 1:05-cv-12237-WGY

Document 485

Filed 06/11/2007

Page 4 of 4

19. 2006).

Exhibit 17 is a true and correct copy of MPEP §706.03(d) (8th ed. Rev. 5, Aug.

Dated: June 11, 2007

Respectfully submitted, /s/ Krista M. Rycroft Krista M. Rycroft CERTIFICATE OF SERVICE

I hereby certify that this document filed through the ECF system will be sent electronically to the registered participants as identified on the Notice of Electronic Filing (NEF) and paper copies will be sent to those indicated as non registered participants on the above date. /s/ Nicole A Rizzo Nicole A. Rizzo
03099/00501 684745.1

4